Search Results - (Author, Cooperation:I. Murata)
-
1Latest Papers from Table of Contents or Articles in PressStaff View
Publication Date: 2018-05-03Publisher: Institute of Physics Publishing (IOP)Electronic ISSN: 1748-0221Topics: PhysicsPublished by: -
2Latest Papers from Table of Contents or Articles in PressE. Mahieu ; M. P. Chipperfield ; J. Notholt ; T. Reddmann ; J. Anderson ; P. F. Bernath ; T. Blumenstock ; M. T. Coffey ; S. S. Dhomse ; W. Feng ; B. Franco ; L. Froidevaux ; D. W. Griffith ; J. W. Hannigan ; F. Hase ; R. Hossaini ; N. B. Jones ; I. Morino ; I. Murata ; H. Nakajima ; M. Palm ; C. Paton-Walsh ; J. M. Russell, 3rd ; M. Schneider ; C. Servais ; D. Smale ; K. A. Walker
Nature Publishing Group (NPG)
Published 2014Staff ViewPublication Date: 2014-11-07Publisher: Nature Publishing Group (NPG)Print ISSN: 0028-0836Electronic ISSN: 1476-4687Topics: BiologyChemistry and PharmacologyMedicineNatural Sciences in GeneralPhysicsPublished by: -
3Articles: DFG German National LicensesIsomoto, H. ; Inoue, K. ; Furusu, H. ; Enjoji, A. ; Fujimoto, C. ; Yamakawa, M. ; Hirakata, Y. ; Omagari, K. ; Mizuta, Y. ; Murase, K. ; Shimada, S. ; Murata, I. ; Kohno, S.
Oxford, UK : Blackwell Science Ltd
Published 2003Staff ViewISSN: 1365-2036Source: Blackwell Publishing Journal Backfiles 1879-2005Topics: MedicineNotes: Background : There is currently no optimal second-line treatment after failure of Helicobacter pylori triple therapy.Aim : To determine effective salvage therapy after failure of lansoprazole–amoxicillin–clarithromycin.Methods : After failure of lansoprazole–amoxicillin–clarithromycin 123 out-patients were randomized to receive either 2-week rabeprazole (20 mg b.d.) + amoxicillin (1000 mg b.d.) (RA group) or 1-week rabeprazole (10 mg b.d.) + amoxicillin (750 mg twice b.d.) + metronidazole (250 mg b.d.) (RAM group). Eradication was assessed by the 13C-urea breath test. We also evaluated cytochrome p450 (CYP) 2C19 genotype status, determined by polymerase chain reaction – restriction fragment length polymorphism, and susceptibility to clarithromycin and metronidazole.Results : On an intention-to-treat basis, H. pylori infection cure was achieved in 37 of 63 (59%) patients in the RA group and in 49 of 60 (82%) patients in the RAM group. Per protocol-based eradication rates in the RA and RAM groups were 66% (37/56) and 88% (49/56), respectively. In both analytic sets there were significant differences between the treatment groups (P 〈 0.01 in each). Mild adverse events were observed in eight and five patients from the RA and RAM groups, respectively. Genetic predisposition of CYP2C19 and antibiotic resistance did not influence the treatment outcome either regimen.Conclusions : The rabeprazole + amoxicillin + metronidazole therapy yielded satisfactory results. In contrast, the cure rate in high-dose rabeprazole + amoxicillin was below an acceptable level.Type of Medium: Electronic ResourceURL: -
4Articles: DFG German National LicensesIsomoto, H. ; Furusu, H. ; Morikawa, T. ; Mizuta, Y. ; Nishiyama, T. ; Omagari, K. ; Murase, K. ; Inoue, K. ; Murata, I. ; Kohno, S.
Oxford UK : Blackwell Science Ltd
Published 2000Staff ViewISSN: 1365-2036Source: Blackwell Publishing Journal Backfiles 1879-2005Topics: MedicineNotes: To determine whether a 5-day regimen with rabeprazole, clarithromycin and amoxicillin (RCA) was as effective as a 7-day regimen.〈section xml:id="abs1-2"〉〈title type="main"〉Methods:A total of 139 H. pylori-infected patients were randomized to receive either a 5-day or 7-day course of rabeprazole 10 mg b.d., clarithromycin 400 mg b.d. and amoxicillin 750 mg b.d. Eradication was assessed by CLO test, histology and 13C-urea breath test.〈section xml:id="abs1-3"〉〈title type="main"〉Results:On the intention-to-treat basis, eradication rates were 66% (46 out of 70) and 84% (58 out of 69) for the 5- and 7-day regimens, respectively (P 〈 0.05). Using per protocol analysis, eradication rates were 70% (46 out of 66) and 91% (58 out of 64) for the 5- and 7-day regimens, respectively (P 〈 0.01). Adverse events, which were observed in 14 patients from each group, caused discontinuation of treatment in only two patients, resulting in excellent compliance.〈section xml:id="abs1-4"〉〈title type="main"〉Conclusions:Our 5-day regimen of RCA yielded inferior results, whereas the 7-day regimen achieved an eradication rate exceeding 90% on the per protocol basis. Therefore, treatment regimens of less than 7 days for proton pump inhibitor–clarithromycin–amoxicillin therapies cannot be recommended.Type of Medium: Electronic ResourceURL: -
5Articles: DFG German National LicensesYoshikawa, I. ; Murata, I. ; Kume, K. ; Kanagawa, K. ; Hirohata, Y. ; Nakamura, H. ; Otsuki, M.
Oxford, UK : Blackwell Science Ltd
Published 2002Staff ViewISSN: 1365-2036Source: Blackwell Publishing Journal Backfiles 1879-2005Topics: MedicineNotes: Background : Therapy for the relief of symptoms of functional dyspepsia is unpredictable.Aim : To identify which patients may benefit from antisecretory therapy.Methods : Twenty-seven patients with functional dyspepsia were selected to receive H2-receptor antagonist (H2RA) treatment for 4 weeks. Serum pepsinogen A, pepsinogen C and gastrin were measured, and Helicobacter pylori status was determined. Symptoms were assessed at baseline and after H2RA treatment.Results : Fourteen patients were identified as H2RA responders and the remaining patients were non-responders. No differences were found between responders and non-responders with regard to serum pepsinogen A, pepsinogen C, gastrin and H. pylori status. However, the pepsinogen A/C ratio was significantly higher in responders than in non-responders. Ten of the 13 functional dyspepsia patients (77%) with a high value of the pepsinogen A/C ratio (≥ 4.5) achieved symptom resolution by H2RA, compared with only one of the eight patients (13%) with a low value of the pepsinogen A/C ratio (≤ 3.0).Conclusions : The serum pepsinogen A/C ratio seems to identify those functional dyspepsia patients for whom acid control provides benefit. This ratio may be a practical tool for the management of functional dyspepsia patients.Type of Medium: Electronic ResourceURL: -
6Articles: DFG German National LicensesStaff View
ISSN: 0006-291XSource: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002Topics: BiologyChemistry and PharmacologyPhysicsType of Medium: Electronic ResourceURL: -
7Articles: DFG German National LicensesStaff View
ISSN: 0040-4020Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002Topics: Chemistry and PharmacologyType of Medium: Electronic ResourceURL: -
8Articles: DFG German National LicensesStaff View
ISSN: 0040-4020Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002Topics: Chemistry and PharmacologyType of Medium: Electronic ResourceURL: -
9Articles: DFG German National LicensesStaff View
ISSN: 0040-4020Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002Topics: Chemistry and PharmacologyType of Medium: Electronic ResourceURL: -
10Articles: DFG German National LicensesSugihara, Y. ; Miyatake, R. ; Yagi, T. ; Murata, I. ; Jinguji, M. ; Nakazawa, T. ; Imamura, A.
Amsterdam : ElsevierStaff ViewISSN: 0040-4020Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002Topics: Chemistry and PharmacologyType of Medium: Electronic ResourceURL: -
11Articles: DFG German National LicensesStaff View
ISSN: 0584-8539Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002Topics: Chemistry and PharmacologyPhysicsType of Medium: Electronic ResourceURL: -
12Articles: DFG German National LicensesStaff View
ISSN: 0006-291XSource: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002Topics: BiologyChemistry and PharmacologyPhysicsType of Medium: Electronic ResourceURL: -
13Articles: DFG German National LicensesStaff View
ISSN: 0009-2614Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002Topics: Chemistry and PharmacologyPhysicsType of Medium: Electronic ResourceURL: -
14Articles: DFG German National LicensesStaff View
ISSN: 0009-2614Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002Topics: Chemistry and PharmacologyPhysicsType of Medium: Electronic ResourceURL: -
15Articles: DFG German National LicensesStaff View
ISSN: 0040-4039Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002Topics: Chemistry and PharmacologyType of Medium: Electronic ResourceURL: -
16Articles: DFG German National LicensesStaff View
ISSN: 0040-4039Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002Topics: Chemistry and PharmacologyType of Medium: Electronic ResourceURL: -
17Articles: DFG German National LicensesStaff View
ISSN: 0040-4039Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002Topics: Chemistry and PharmacologyType of Medium: Electronic ResourceURL: -
18Articles: DFG German National LicensesStaff View
ISSN: 0040-4039Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002Topics: Chemistry and PharmacologyType of Medium: Electronic ResourceURL: -
19Articles: DFG German National LicensesStaff View
ISSN: 0040-4039Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002Topics: Chemistry and PharmacologyType of Medium: Electronic ResourceURL: -
20Articles: DFG German National LicensesStaff View
ISSN: 0040-4039Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002Topics: Chemistry and PharmacologyType of Medium: Electronic ResourceURL: